Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Paracetamol + amantadine hydrochloride** is a fixed-dose combination drug primarily used for symptomatic relief of common cold and influenza symptoms, including fever, headache, nasal congestion, rhinorrhea, sneezing, sore throat, and limb pain, as well as for influenza prevention and treatment. Paracetamol (acetaminophen) acts as an antipyretic and analgesic by inhibiting prostaglandin synthesis. Amantadine hydrochloride is an antiviral agent that inhibits influenza A virus replication by blocking the viral M2 ion channel and also has anticholinergic and dopaminergic effects that enhance analgesia and reduce symptoms. Formulations often include additional excipients like chlorphenamine maleate (antihistamine), caffeine (central stimulant to potentiate analgesia and counter sedation), and artificial Calculus Bovis (antipyretic and anticonvulsant). Developed in China, it is available as capsules (e.g., 0.377g, containing 250mg paracetamol and 100mg amantadine HCl) or tablets, administered orally.[1][3][5][9][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on paracetamol + amantadine hydrochloride.